Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025
Rhea-AI Summary
Skye Bioscience (Nasdaq: SKYE) will report third quarter 2025 financial results and host a business update call on November 10, 2025 at 1:30 p.m. PT / 4:30 p.m. ET.
The company will issue its earnings press release and financial tables after market close on November 10, 2025. A live webcast and investor presentation will be available on the Skye Investor Relations website, with a replay posted after the call.
Skye will also present at the Stifel 2025 Healthcare Conference in New York on November 13, 2025 from 4:40–5:10 PM and will be available for one‑on‑one meetings.
Positive
- None.
Negative
- None.
News Market Reaction 5 Alerts
On the day this news was published, SKYE gained 6.34%, reflecting a notable positive market reaction. Argus tracked a peak move of +7.4% during that session. Argus tracked a trough of -4.8% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $3M to the company's valuation, bringing the market cap to $50M at that time.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on advancing new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Monday, November 10, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss its third quarter 2025 financial results. The Company will issue its financial results and business update press release after the market closes on the same day.
The live webcast of the call can be accessed at the Skye Investor Relations website, along with the company's earnings press release, financial tables, and investor presentation. Please join the call 5-10 minutes prior to the scheduled start time. Following the call, a replay will be available at the same website.
Skye will also be presenting at the Stifel 2025 Healthcare Conference in New York on Thursday, November 13 at 4:40-5:10 PM and will be available for 1x1 meetings.
About Skye Bioscience
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on LinkedIn.
CONTACTS
Investor Relations
ir@skyebioscience.com
(858) 410-0266
LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306
Media Inquiries
LifeSci Communications, Michael Fitzhugh
mfitzhugh@lifescicomms.com
(628) 234-3889
FAQ
When will Skye Bioscience (SKYE) announce Q3 2025 results and hold the earnings call?
Where can investors access the Skye Bioscience (SKYE) live webcast and earnings materials?
When will Skye Bioscience (SKYE) issue its Q3 2025 press release?
Will there be a replay of the Skye Bioscience (SKYE) Q3 2025 earnings call?
When and where will Skye Bioscience (SKYE) present at the Stifel 2025 Healthcare Conference?
What should investors do before the scheduled Skye Bioscience (SKYE) earnings call start time?
